Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers
Recruitment status was Active, not recruiting
|First Received Date ICMJE||January 4, 2013|
|Last Updated Date||December 9, 2013|
|Start Date ICMJE||January 2013|
|Estimated Primary Completion Date||June 2014 (final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Frequency of heavy drinking days per week by medication group [ Time Frame: 11-week study period ] [ Designated as safety issue: No ]
Number of heavy drinking days (>4 drinks for men; >3 drinks for women) for each participant during the study period. Two-level hierarchical linear models will examine the main effect of Medication Group and the Medication Group x Time interaction.
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01764685 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers|
|Official Title ICMJE||Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers|
|Brief Summary||Heavy drinking (HD) is a risk factor for HIV transmission and is more common in HIV+ individuals than in the general population. HD adversely affects health directly and reduces adherence to antiretroviral therapies (ARTs), in part due to alcohol-induced cognitive impairment. Reduced drinking improves cognitive performance and adherence to ARTs. Medications approved in the United States to treat alcohol dependence have a small effect size. However, topiramate, FDA-approved as an anticonvulsant and a prophylaxis for migraine, has a greater effect size in reducing drinking and promoting abstinence in alcohol dependent individuals. To date, there are no studies of the effects of topiramate in HIV+ heavy drinkers. The investigators propose to conduct a randomized, parallel-groups, placebo-controlled, 11-week trial of topiramate in 40 HIV+ heavy drinkers who want to reduce or stop their drinking. There are three primary hypotheses for this feasibility and proof-of-concept study. First, the investigators hypothesize that topiramate-treated patients will decrease the frequency of their HD more than placebo-treated patients. Second, based on scores from computerized neurocognitive assessments, the investigators hypothesize that topiramate and placebo groups will show similar performance on a battery of cognitive tests. Third, based on self-reported medication adherence, the investigators hypothesize that adherence to ARTs will be greater in the topiramate group than in the placebo group. These findings will provide preliminary data to support a more definitive trial of topiramate for the treatment of HD in HIV+ heavy drinkers.|
A. General Design: This study will employ an 11-week, parallel-groups design (TOP vs. placebo) to test the effects of topiramate (TOP) on HD by HIV+ individuals with a current alcohol use disorder. We will gradually increase the dosage of TOP from 25 mg/day to 150 mg/day over a 6-week period to minimize adverse events. Random assignment to treatment group and double-blind conditions will be maintained throughout the study.
B. Recruiting: HIV+ men and women will be recruited through advertisements and by collaboration with physicians in the University of Pennsylvania Health System (UPHS) who will be invited to refer patients for whom heavy drinking in their HIV+ patients has created medical concerns. Patients will be recruited using the following methods: through referrals to the research center at the University of Pennsylvania (UPenn); by posting/distributing recruitment materials in community settings with public posting areas or other means of providing community access to materials (such as hospitals, town halls, public libraries, YMCA, health fairs/organizations); and through advertisements in local media (including text ads in newspapers, magazines; radio ads on local radio stations; web ads on internet sites and web postings on community message boards and research listings). These methods have been successful for Dr. Kranzler at the University of Pennsylvania and for many investigators at the Treatment Research Center (TRC) at UPenn. The TRC is an active center for clinical investigation and the staff and faculty there are highly experienced and capable in the conduct of clinical trials such as this. We will use institution-approved recruitment materials to advertise for regular or daily drinkers who are HIV+ and want to reduce their drinking. We will obtain permission at selected locations before distributing or posting the approved recruitment materials (to ensure that we comply with other institutions' guidelines). We anticipate that approximately 40% of patients will be women and that minority patients will be represented at least in proportion to the general population in Philadelphia. Based upon the large number of potential patients and our success in recruitment for prior studies, including those involving heavy drinkers, we are confident of our ability to achieve our recruitment goals.
C. Study Visits: At the screening visit, patients will provide informed consent and their reading ability will be evaluated, a medical and psychiatric history obtained. Blood and urine samples will be taken for routine clinical laboratory evaluations (including GGTP), drug screening, and pregnancy testing in females of reproductive potential. Patients will be interviewed with the Structured Clinical Interview for DSM-IV (SCID). Patients who are excluded will be referred to treatment.
The baseline visit will occur 1-14 days after the screening visit. Eligible patients will undergo a research evaluation, complete a packet of questionnaires, complete cognitive testing, and be interviewed by the research assistant. A physical examination will be performed by a study physician or nurse practitioner. Eligible patients will receive their first counseling session and first supply of study medication during a subsequent treatment session the same day. We will use urn randomization, a probabilistic balancing procedure to assign patients to medication group so that groups are balanced on key variables (Wei 1978): sex, race (white or non-white), number of HD days in past month.
During the 11-week treatment period, patients will return to the clinic weekly for five weeks while the dosage of the medication is gradually increased and then biweekly for six weeks. For patient safety during travel, they will be instructed not to drink prior to study visits. At each visit, the patient's breath alcohol level, weight, and vital signs will be measured. They will complete questionnaires and cognitive testing, and be interviewed by the research nurse about their use of concurrent medications, the occurrence of adverse events, and protocol compliance and then receive the medical management intervention. During visit 9 (end of treatment week 11), patients will complete questionnaires and cognitive testing and be interviewed by the research evaluator concerning their alcohol consumption. Patients will be compensated for this end-of-treatment visit. Patients will also be interviewed by the research nurse about their use of concomitant medications, occurrence of adverse events, compliance with the protocol, and their assessment of the effectiveness and acceptability of the treatment procedures (through the Medication Questionnaire; MED-Q). The nurse will dispense 4 days of medication for the taper and instruct the patient on how to take the medication during this period. Blood samples to measure serum GGTP will be obtained to assess the validity of self-reported drinking. A study nurse or research coordinator will call the patient one week after the endpoint visit to confirm that the subject completed the medication taper. Continuing adverse events will be followed by the study nurse and physician to their conclusion, as is feasible. Patients requesting (or clearly needing) additional treatment for alcohol problems will be referred to local treatment centers. All patients (including those who discontinue treatment prematurely) will be asked to complete an end-of-treatment evaluation and to complete all scheduled assessments to facilitate intention-to-treat (ITT) analyses. For patients who withdraw early and do not wish to continue with study visits/procedures, all end-of-treatment procedures will be administered at the time of withdrawal. Such patients will also be asked to undergo in-person or telephone follow-up at end-of-treatment for collection of the remaining treatment-phase Timeline Followback (TLFB) data.
D. Compensation: Patients will be compensated for their time and transportation.
E. Study Treatments: Throughout the study, we will maintain double-blind conditions with respect to medication administration. The research nurse, who is experienced in the conduct of alcohol pharmacotherapy trials, will deliver the medical management and monitor the medication, including capsule counts to measure adherence. The physician will meet with the patient initially, meet at least weekly with the nurse to discuss progress, and evaluate the patient in the event of severe or persistent adverse effects. The nurse will dispense study medications prescribed by the physician. Patients with severe psychological symptoms (e.g., suicidal thoughts) will be withdrawn from treatment and referred for appropriate clinical care. An effort will be made to obtain outcome information on all randomized patients for ITT analysis. In the medication condition, TOP will be administered at a maximum of 150 mg/day in two divided doses. TOP will be purchased commercially and formulated in opaque capsules by the Investigational Drug Service (IDS) at the University of Pennsylvania School of Medicine, which will purchase the TOP commercially and formulate the medication in capsules. Placebo will be formulated to match the active medication, such that inspection of the capsules will not permit the two to be differentiated.
Laboratory/Medical Assessments: These assessments are included to screen patients for medical exclusion criteria, assess potential adverse effects of medications, and corroborate self-reported drinking. Prior to entrance into the study, each patient will receive:
At the midpoint and end of the 11-week treatment phase, GGTP will be repeated to corroborate self-reported alcohol consumption. In addition to eliciting self-reported adverse events, weight and vital signs (blood pressure and pulse) will be obtained at each treatment visit.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 2|
|Study Design ICMJE||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Study Arm (s)||
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Active, not recruiting|
|Estimated Enrollment ICMJE||60|
|Estimated Completion Date||January 2015|
|Estimated Primary Completion Date||June 2014 (final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||18 Years to 70 Years|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT01764685|
|Other Study ID Numbers ICMJE||816082|
|Has Data Monitoring Committee||No|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Henry Kranzler, University of Pennsylvania|
|Study Sponsor ICMJE||University of Pennsylvania|
|Collaborators ICMJE||Not Provided|
|Information Provided By||University of Pennsylvania|
|Verification Date||December 2013|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP